UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Adjuvant temozolomide for low grade gliomas: Molecular and
radiographic correlates of treatment response in a phase II clinical trial.
Authors*: Michael Traut Wahl, Joanna J Phillips, Annette M Molinaro, Yi Lin, Arie Perry,
Daphne Haas-Kogan, Joseph F Costello, Manisha Dayal, Nicholas A. Butowski, Jennifer Leigh Clarke,
Michael Prados, Mitchel S. Berger, Sarah J. Nelson, Susan Marina Chang
Abstract #: 2002
Presentation Date/Time: Sunday, June 5: 8:00 - 11:00 AM
Location: S100a
Oral Abstract Session: Central Nervous System Tumors
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2002)
Chang Research Interests: My research interest is in the development of novel therapies for patients with
brain tumors, as well as the assessment of novel imaging biomarkers in the management of patients.
My research seeks to integrate advances in physiologic and metabolic imaging with tissue biomarkers in
order to optimize the management of patients with glioblastoma (GBM). My clinical research evaluates a
wide spectrum of therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and
convection enhanced delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor
consortium and am a member of the Brain Malignancy Steering Committee and the Developmental
Therapeutics Study Section at the NIH. I am the program leader for the Neuro-Oncology Program at the
HDFCCC. I am the clinical co-PI for the UCSF Brain Tumor SPORE and a co-Leader of a SPORE Project
evaluating the role of physiologic imaging in the determination of malignant progression of low-grade glioma.
http://cancer.ucsf.edu/people/profiles/chang_susan.3565
*UCSF authors in bold
43